Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial infections, announced that the Korean Intellectual Property Office (KIPO) has granted a new patent which covers DNA Polymerase IIIC inhibitors including compositions‑of‑matter, methods of use, and pharmaceutical compositions, which further strengthen Acurx's intellectual property portfolio and represents the most recent addition to its expanding series of granted patents in the U.S. and abroad. To date, Acurx has secured four U.S. patents, along with granted patents in Israel, Japan, India, Australia and Korea, all of which protect key aspects of the Company's ACX‑375C program targeting DNA Polymerase IIIC. Additional country‑level patent applications remain under review.

Robert J. DeLuccia, Executive Chairman of Acurx, stated: "Achieving this new patent extends our patent estate protection as we further develop our innovative, AI-supported drug discovery platform. We believe Acurx's preclinical pipeline of systemically-absorbed compounds has the potential to create a transformational shift in the treatment paradigm of serious and potentially life-threatening infections such as acute bacterial skin and skin-structure infections (ABSSSI, including MRSA), Community-acquired bacterial pneumonia (CABP), hospital and/or ventilator-associated bacterial pneumonia (HABP/VABP), bacteremia with or without sepsis and/or infectious endocarditis, bone/joint infections, prosthetic joint infections and inhalational anthrax, caused by B. anthracis, a Bioterrorism Category A Threat-Level pathogen. Recently presented microbiome selectivity data on representative novel compounds provide initial evidence that microbiome selectivity, when compared to the comparator antibiotic, linezolid, may be a class effect."

He further stated: "Our lead DNA pol IIIC inhibitor, ibezapolstat, is ready to advance to international, Phase 3, pivotal registration trials in the US and EU for oral treatment of acute C. difficile Infection. We're also starting up a ground-breaking clinical trial with ibezapolstat in patients with multiply-recurrent CDI (rCDI) that has the potential to shift the treatment paradigm for acute CDI and rCDI from two agents to one."